BOSTON--(BUSINESS WIRE)--LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, today announced the continued expansion of its strategic communications team with the hiring of Paul Sagan, who is joining LHS as Assistant Vice President, Investor Relations and Corporate Communications, effective today. Paul joins LHS from KCSA Strategic Communications, where he was Vice President, Corporate Communications & Investor Relations and worked with a variety of health, science and technology-based clients.
Paul has more than 20 years of experience in counselling both privately-held as well as publicly-held companies on investor relations, corporate and marketing communications matters and has served as an executive with several leading Wall Street and New England-based consultancies, including senior financial communications positions at Sharon Merrill Associates, Morgan-Walke Associates, Thermo Electron Corporation, Allmerica Financial and Camp Dresser & McKee.
Skilled at communicating complex information about his life science clients to both the investment community and to the general public, Paul has advised more than 50 companies - from venture-backed startups to multi-national corporations.
“I’m excited to join LaVoieHealthScience, whose focus on integrated communications and domain expertise in the life sciences is unique,” said Paul. “The firm’s multi-disciplinary approach to IR, corporate communications and financial media relations has helped companies further their growth trajectory. I look forward to helping our clients - some of the luminaries in the life science field - achieve increased value for their innovations.”
As a member of the Senior Leadership Team at LHS, Paul will work with the practice leads in investor and public relations and support the respective practices and clients at the intersection of Science, Healthcare and Technology. Paul will also work as an advocate and facilitator of organizational growth for the firm.
Donna L. LaVoie, President & CEO commented, “With our keen focus on aligning with health, science and technology innovators, Paul’s expertise in strategic positioning and his relationships with institutional investors, analysts, and the media will be important to our firm’s continued success. Paul’s broad experience will be a strong addition to our existing team and an asset to our current and future clients.”
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides strategic communications, investor relations and public relations to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and is ranked among the 2017 Inc. 5000 list of fastest growing private companies for the fourth year. In addition to clients listed above, LaVoieHealthScience represents leaders such as Affimed, BioAxone BioSciences, Biotechnology Innovation Organization, Fusion Pharmaceuticals, Genosco, Landos Biopharma, LEO Science Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Biosystems, Prescriber's Choice, Scioto Biosciences, Symbiotix, Triumvira Immunologics, Xontogeny LLC, and other emerging health and science companies.